AG
RAPP

Artal Group’s Rapport Therapeutics RAPP Stock Holding History

Artal Group’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-350,000
Closed -$8.14M – 104
2024
Q2 		$8.14M Buy
+350,000
New +$8.1M 0.21% 45

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group's RAPP Position: Q3 2024 in Review

Artal Group sold out of Rapport Therapeutics (RAPP) in Q3 2024, closing a stake of 350,000 shares — an estimated $8.14M sold.

Artal Group first reported a position in RAPP in Q2 2024 and held it in 1 quarter. The position peaked at $8.14M in Q2 2024. 55 funds tracked by Wall St. Rank hold RAPP as of Q3 2024.

  • Artal Group reported no remaining Rapport Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 350,000 Rapport Therapeutics shares in Q3 2024, an estimated $8.14M.
  • Artal Group first reported a position in Rapport Therapeutics in Q2 2024 and held it in 1 quarter.
  • Artal Group's Rapport Therapeutics position peaked at $8.14M in Q2 2024.
  • 55 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.